Jones Financial Companies
CRNX

Jones Financial Companies’s Crinetics Pharmaceuticals CRNX Stock Holding History

Jones Financial Companies’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$790K Buy
21,531
+5,248
+32% +$195K ﹤0.01% 2013
2026
Q1 		$548K Buy
16,283
+16,225
+27,974% +$725K ﹤0.01% 1999
2025
Q4 		$2.7K Buy
+58
New +$2.58K ﹤0.01% 3725
2025
Q3 		– Sell
-27
Closed -$809 – 4255
2025
Q2 		$809 Buy
+27
New +$834 ﹤0.01% 3707

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jones Financial Companies's CRNX Position: Q2 2026 in Review

Jones Financial Companies increased its Crinetics Pharmaceuticals (CRNX) stake by 32% in Q2 2026, buying an estimated $195K and bringing the position to 21,531 shares worth $790K. The position accounts for ﹤0.01% of the portfolio, ranked #2013.

Jones Financial Companies first reported a position in CRNX in Q2 2025 and has held it in 4 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Jones Financial Companies held 21,531 shares of Crinetics Pharmaceuticals worth $790K as of Q2 2026.
  • Jones Financial Companies bought 5,248 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $195K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #2013 holding.
  • Jones Financial Companies first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.